Based on the evidence that (a) thiazolidinedionescan suppress inflammatory gene expression in vitro and (b) PPARγ expression protects against the developmentof colitis in several animal models, it seems logical that PPARγ might be a good target for treatment ofgut inflammation. This evidence concerns the gene PPARG and colitis.